Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Takeda Files Nesina-Metformin Combo Drug in Japan
September 29, 2015
- Celgene Launches Japan PI for Pleiotropic Pathway Modifier
September 29, 2015
- Chugai to Create New Post to Gear Up for HTA Introduction
September 28, 2015
- Maruho Files NDA for Japan’s First Infantile Hemangioma Treatment
September 28, 2015
- MEDINET Partners with Univ. of Tokyo in Joint Research for iPS Immuno-Cell Therapy
September 28, 2015
- Nihon Generic to Build New Factory with 10 Billion-Tablet Capacity
September 25, 2015
- MTPC, MedImmune Hook Up on Antibody Drug Conjugates
September 25, 2015
- NICE Recommends New Lixiana Indication for Health Coverage: Daiichi Sankyo
September 25, 2015
- Taiho Gets FDA Nod for Lonsurf, Its First Approval in US
September 25, 2015
- Terumo Aims at Annual Sales of 1-2 Billion Yen for HeartSheet within 5-10 Years
September 25, 2015
- Achieving New Share Target for Generics Will Be “Quite Difficult”: Hengrui Japan President
September 25, 2015
- Japan Approves JCR Pharma’s Cell-Based Acute GVHD Treatment
September 24, 2015
- Japan Grants 1st Conditional Approval to Terumo’s HeartSheet
September 24, 2015
- Novartis Files Afinitor for GI and Lung Neuroendocrine Tumors in Japan
September 24, 2015
- Amgen Gets Rights to MTPC’s Dyslipidemia Drug after Dezima Acquisition
September 18, 2015
- Chugai Seeks Cervical Cancer Indication for Avastin
September 18, 2015
- Opdivo Gets Breakthrough Therapy Designation for RCC
September 18, 2015
- 1 in 4 Elderly Japanese on 5 or More Prescribed Meds: Pharmacy Survey
September 17, 2015
- Eli Lilly’s Once-Weekly GLP-1 Hits Japan Market
September 17, 2015
- RaQualia Won’t Rule Out Control by Another Firm, Eyes Black Ink in 2018-2019: CEO
September 16, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…